1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug

 
• By Alaric DeArment

The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.

Verve announced the dosing of the first patient in the trial of its Phase Ib study of VERVE-101 in HeFH • Source: Shutterstock

Verve Therapeutics, Inc. has reached the clinic earlier than anticipated with its base-editing medicine for lowering cholesterol, bringing it into the growing group of PCSK9-targeting therapies looking to succeed where marketed drugs from Amgen, Inc. and Sanofi/Regeneron Pharmaceuticals, Inc. have largely failed.

The company said 12 July that it dosed the first patient in the Phase Ib heart-1 clinical trial of VERVE-101,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

 
• By Mandy Jackson

The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

More from Advanced Therapies

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

 
• By Mandy Jackson

The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.